The Ministry of Health recently approved fecal calprotectin testing for BC patients treated with a biologic agent (e.g. adalimumab, infliximab or vedolizumab). Starting August 15, 2019, fecal calprotectin testing is available for patients who meet this clinical requirement. Fecal calprotectin testing for other clinical indications is not approved at this time, and therefore, is not funded by the Ministry after August 15.
Calprotectin is a protein released from white blood cells during the inflammatory process. Patients with Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, have high levels of calprotectin in their stool. Fecal calprotectin is a non-invasive test used to monitor disease status and treatment efficacy. The amount of fecal calprotectin in a stool sample is proportional to the amount of intestinal inflammation; increases and decreases in fecal calprotectin concentration reflect bowel damage and healing, respectively.
Fecal calprotectin testing can be requested using the Standard Outpatient Laboratory Requisition. Only patients receiving biologic agents are eligible for MSP payable testing. Requests for all other clinical indications are patient pay. For more information, please refer to the bulletins below.